GlassScriptPhysician profile
Cristin Campbell
NPI 1235731670
$2,721.15
in general payments reported to CMS, 2019-2025
17 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $365 · 2024: $1,176 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,632 · Education: $89.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.67 |
| Education | $89.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,302.74 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $349.43 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $228.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $199.55 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $135.66 | 2024-2025 | |
| Gilead Sciences, INC. | $134.21 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $91.53 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.80 | 2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $39.52 | 2024-2025 | Eohilia, Entyvio |
| Novo Nordisk INC | $30.01 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $22.85 | 2025 | |
| Mallinckrodt Hospital Products INC. | $20.73 | 2024 | Terlivaz |
| Redhill Biopharma INC. | $19.33 | 2024 | Aemcolo, Talicia |
| Shield Therapeutics INC | $18.14 | 2024 | |
| Braintree Laboratories, INC. | $17.83 | 2023 | Sutab, Suflave |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $14.29 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristin Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.